Insilico, Juvenescence and the Buck Institute form AI-based venture to tackle metabolism and aging-related diseases

A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to extend life spans.